3results about How to "Potential for clinical application" patented technology

This invention discloses a Litsea cubeba extract, its preparation method, and its applications, relating to the field of pharmaceutical compound technology. The Litsea cubeba extract has the structural formula shown in Formula I: (Formula I). ​​This Litsea cubeba extract is isolated from the Litsea cubeba plant. This novel compound can significantly inhibit NO production in an LPS-induced RAW264.7 cell inflammation model; alleviate the immune-inflammatory response in an in vitro 3D skin model of atopic dermatitis; inhibit epidermal thickening and repair skin barrier function; and reduce the inflammatory response by inhibiting the PI3K / Akt signaling pathway. It has clinical application potential in the treatment of atopic dermatitis and can be used to prepare anti-atopic dermatitis drugs, showing promising application prospects.

The invention discloses a composite ice inhibitor, a vitrification protective agent and a blood vessel cryopreservation method, and belongs to the field of cryopreservation or vitrification preservation of vascularized tissues and organs. According to the volume of 100 mL of the composite ice inhibiting agent, the composite ice inhibiting agent is prepared from 10 to 500 g of polyvinyl alcohol, 10 to 500 g of polyglycerol, 10 to 500 g of trehalose, 10 to 500 g of L-proline, 10 to 500 g of polyvinylpyrrolidone, 10 to 500 g of polyethylene glycol 6000 and the balance of ultrapure water, and the total volume of the composite ice inhibiting agent is 100 mL. According to the volume of 1L of the vitrification protective agent, the vitrification protective agent contains 1.65 to 2.2 mol of dihydric alcohol, 2.3 to 3.1 mol of dimethyl sulfoxide, 2.3 to 3.1 mol of formamide, 12 to 57 mmol of a pH buffer solution, 0.39 to 1.93 mmol of a composite ice inhibitor and the balance of ultrapure water, wherein the total volume is 1L; the compound ice inhibiting agent has the advantages that the solution damage is reduced, the ice inhibiting performance is better, and the damage to cells caused by extra osmotic pressure is reduced under the minimum use metering. The composite ice inhibitor is especially suitable for cryopreservation of endothelial cells, smooth muscle cells and blood vessels.

The invention discloses application of RGS14 in preparation of a kit for auxiliary diagnosis or prognosis of liver cancer and application of an RGS14 expression inhibitor in preparation of a medicine for treating liver cancer. It is found for the first time that RGS14 expression in liver cancer is remarkably improved compared with para-carcinoma tissue, and high RGS14 expression is not beneficial to overall survival of liver cancer patients; and when the RGS14 is knocked down, the clone formation and migration of the liver cancer cells are obviously inhibited. The high expression of the RGS14 is closely related to the poor prognosis of the liver cancer patient, which prompts that the RGS14 can be used as a prognosis marker of the liver cancer, and effective information is provided for prognosis evaluation and curative effect monitoring of the liver cancer. The invention also provides an RGS14 expression inhibitor siRNA which has a good interference effect when being used for inhibiting the expression of RGS14 and has clinical application potential.